910 completed, 280 terminated, 265 recruiting, 190 unknown. 815 Phase 2, 609 Phase 1, 226 Not applicable, 122 Phase 3, 32 Early Phase 1.
Follow Carcinoma, Renal Cell: new trials by email Literature Review of Carcinoma, Renal Cell trials Research Report on Carcinoma, Renal Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial Balstilimab, Biospecimen Collection, Botensilimab - Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 16 | 2027-05-17 | 2026-10-21 |
| Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma Biospecimen Collection, Bone Scan, Computed Tomography - Non-Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 | Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 400 | 2027-02-10 | 2026-07-08 |
| SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma Stereotactic Body Radiation Therapy (SBRT), Anlotinib, Bemarituzumab - Locally Advanced or Metastatic Renal Cell Carcinoma | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 27 | 2027-02-01 | 2026-10-01 |
| A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors. Signatera Genome ultra-sensitive ctDNA blood test - NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer) | Not applicable | Not yet recruiting | Natera, Inc. | 920 | 2027-01-01 | 2026-10-27 |
| A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC) BMS-986527, Nivolumab, Cabozantinib - Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1 | Not yet recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 112 | 2026-12-31 | 2026-09-30 |
| Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Kidney Carcinoma, Advanced Renal Cell Carcinoma | Phase 1 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 18 | 2026-12-01 | 2026-08-06 |
| A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread Envafolimab+Lenvatinib - Clear Cell Renal Cell Cancer (ccRCC), Liver Metastasis | Phase 2 | Not yet recruiting | Fudan University | 30 | 2026-12-01 | 2026-09-09 |
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell Carcinoma Belzutifan, Pembrolizumab - Locally Advanced Clear Cell Renal Cell Carcinoma | Phase 2 | Not yet recruiting | Peter MacCallum Cancer Centre, Australia | 30 | 2026-12-01 | 2026-10-26 |
| Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy Biospecimen Collection, Bone Scan, C. butyricum CBM 588 Probiotic Strain Capsule Formulation MO-03 - Metastatic Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8 | Phase 2 | Not yet recruiting | City of Hope Medical Center | 34 | 2026-11-28 | 2026-05-11 |
| Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors REGN13089-M404-M2980 - Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 320 | 2026-11-23 | 2026-10-07 |
| Characterizing the Genomic Landscape of Cancer in Native American Populations (NAT-Geno) Bio-specimen Collection, Blood Draw - Prostate Cancer, Renal Cell Carcinoma (RCC) | Recruiting | University of Oklahoma | 300 | 2026-11-02 | 2026-10-13 | |
| A Study of CA9-Targeted CAR Macrophage Therapy in Advanced Clear Cell Renal Cell Carcinoma CM-BA-9 - Clear Cell Renal Cell Carcinoma | Early Phase 1 | Not yet recruiting | Liangyou Gu | 6 | 2026-11-01 | 2026-10-08 |
| Comparing Two Weight Loss Programs for the Prevention of Kidney Cancer Progression Among Patients With Small Renal Masses on Active Surveillance Intermittent Fasting, Continuous Energy Restriction (CER) - Renal Cell Carcinoma (RCC) | Not applicable | Recruiting | Roswell Park Cancer Institute | 20 | 2026-11-01 | 2026-10-16 |
| A Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab for Advanced Renal Cancer Ivonescimab (dose level 1) combined with Cadonilimab, Ivonescimab (dose level 2) combined with Cadonilimab, Ivonescimab combined with Ipilimumab - Renal Cell Carcinoma, Clear Cell | Phase 2 | Not yet recruiting | Summit Therapeutics | 100 | 2026-10-19 | 2026-10-16 |
| Phase 2a Study to Assess Safety and Efficacy of Two 177Lu-TLX250 Dosing Regimens in Advanced Relapsed or Recurrent ccRCC 177Lu-TLX250 - ccRCC, Renal Cell Carcinoma (Kidney Cancer) | Phase 2 | Not yet recruiting | Telix Pharmaceuticals (Innovations) Pty Limited | 40 | 2026-10-15 | 2026-10-13 |
| 68Ga- and 18F-CAIX PET Imaging Study 68Ga-CAIX PET/CT, 18F-CAIX - Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma | Early Phase 1 | Not yet recruiting | Peking University First Hospital | 100 | 2026-10-01 | 2026-10-15 |
| A Study of Treatment Delivery Preference In People With Kidney Cancer Nivolumab Injectable Product, Nivolumab, Pembrolizumab injection - Renal Cell Carcinoma, Kidney Cancer | Phase 4 | Recruiting | Memorial Sloan Kettering Cancer Center | 40 | 2026-09-24 | 2026-10-16 |
| QLESP Block for Pain Control in Robotic Partial Nephrectomy ropivacaine (local infiltration), ropivacaine - Renal Cell Carcinoma (Kidney Cancer), Postoperative Pain | Not applicable | Recruiting | Huazhong University of Science and Technology | 120 | 2026-09-22 | 2026-09-25 |
| CAIX-targeted PET/CT in Solid Tumors 68Ga-CAIX - Malignant Solid Tumors, Clear Cell Renal Cell Carcinoma | Not applicable | Recruiting | Zhongnan Hospital | 100 | 2026-09-21 | 2026-10-13 |
Showing 20 of 1957. Sign in to see all of them.
Kidney Neoplasms (478) · Melanoma (290) · Carcinoma, Non-Small-Cell Lung (285) · Neoplasm Metastasis (169) · Neoplasms (158) · Colorectal Neoplasms (147) · Breast Neoplasms (142) · Carcinoma, Hepatocellular (135) · Ovarian Neoplasms (119) · Squamous Cell Carcinoma of Head and Neck (116) · Stomach Neoplasms (115) · Urinary Bladder Neoplasms (115) · Pancreatic Neoplasms (109) · Prostatic Neoplasms (101)
Female Urogenital Diseases and Pregnancy Complications (1957) · Female Urogenital Diseases (1956) · Male Urogenital Diseases (1956) · Urogenital Diseases (1956) · Neoplasms, Glandular and Epithelial (1951) · Neoplasms by Histologic Type (1948) · Neoplasms by Site (1948) · Urologic Diseases (1948) · Adenocarcinoma (1942) · Kidney Diseases (1936) · Urogenital Neoplasms (1933) · Urologic Neoplasms (1933) · Carcinoma (1915) · Neoplasms (1799) · Kidney Neoplasms (1479)
Sunitinib (145) · Nivolumab (144) · pembrolizumab (137) · Sorafenib (84) · Bevacizumab (77) · Everolimus (73) · cabozantinib (71) · Axitinib (69) · pazopanib (65) · Ipilimumab (64) · aldesleukin (52) · Magnetic Resonance Spectroscopy (47) · Cyclophosphamide (41) · Interleukin-2 (38) · Specimen Handling (38)
National Cancer Institute (NCI) (116) · Pfizer (72) · M.D. Anderson Cancer Center (54) · Novartis Pharmaceuticals (35) · Bristol-Myers Squibb (31) · Bayer (29) · Memorial Sloan Kettering Cancer Center (29) · Merck Sharp & Dohme LLC (25) · City of Hope Medical Center (23) · GlaxoSmithKline (21) · Case Comprehensive Cancer Center (19) · Hoffmann-La Roche (17) · Radboud University Medical Center (16) · RenJi Hospital (16) · Jonsson Comprehensive Cancer Center (15)
United States (1120) · China (210) · France (195) · United Kingdom (161) · Spain (158) · Canada (157) · Italy (149) · Germany (127) · Australia (124) · Netherlands (104) · South Korea (101) · Belgium (78) · Poland (71) · Japan (69) · Russia (64)
Eric Jonasch, MD (12) · Giuseppe Procopio, MD (9) · Sumanta K Pal (9) · Robert J. Motzer, MD (8) · Brian I. Rini, MD (5)
PMID 37146227, PMID 27238653, PMID 28410911, PMID 25577718, PMID 33526329, PMID 32499241, PMID 33058158, PMID 39462179, PMID 22980441, PMID 23964934, PMID 26702763, PMID 26706103, PMID 27279544, PMID 31401903, PMID 33947608, PMID 35304832, PMID 35383907, PMID 36848607, PMID 37526095, PMID 41969229, PMID 21917625, PMID 24338498, PMID 24687826, PMID 25532471, PMID 26406150, PMID 26457466, PMID 26685869, PMID 26969090, PMID 27101285, PMID 29377755, PMID 29439857, PMID 29563634, PMID 29788981, PMID 31371341, PMID 31992108, PMID 32171288, PMID 35031545, PMID 35166465, PMID 35420628, PMID 36064785, PMID 37093350, PMID 38396300, PMID 40712111, PMID 40791544, PMID 41484629, PMID 41861260, PMID 10751849, PMID 10984562, PMID 11282341, PMID 11410496
2023 (21), P30CA033572 (20), 2016 (18), 2018 (13), P30CA043703 (13), 2019 (11), 2015 (9), 2017 (9), 2008 (8), P30CA016672 (8), P30CA072720 (8), U10CA032102 (8), U10CA180820 (8), 2014 (7), 2025 (7)